GlobeNewswire: ImmusanT, Inc. Contains the last 10 of 11 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:20:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/06/25/1874108/0/en/ImmusanT-Discontinues-Phase-2-Clinical-Trial-for-Nexvax2-in-Patients-With-Celiac-Disease.html?f=22&fvtc=4&fvtv=51401ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2® in Patients With Celiac Disease2019-06-25T18:01:43Z<![CDATA[CAMBRIDGE, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, has discontinued the Phase 2 global study for its lead candidate, Nexvax2®, intended as a treatment for celiac disease.]]>https://www.globenewswire.com/news-release/2019/05/29/1856507/0/en/ImmusanT-to-Present-at-the-Jefferies-2019-Healthcare-Conference.html?f=22&fvtc=4&fvtv=51401ImmusanT to Present at the Jefferies 2019 Healthcare Conference2019-05-29T14:17:00Z<![CDATA[CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, announced today the company’s chief executive officer, Leslie Williams, will present an overview of the company and its business at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City.]]>https://www.globenewswire.com/news-release/2019/05/21/1833663/0/en/ImmusanT-Presents-Early-Evidence-Supporting-its-Lead-Therapeutic-Vaccine-Candidate-During-the-Digestive-Disease-Week-Annual-Conference-2019.html?f=22&fvtc=4&fvtv=51401ImmusanT Presents Early Evidence Supporting its Lead Therapeutic Vaccine Candidate During the Digestive Disease Week Annual Conference 20192019-05-21T16:12:00Z<![CDATA[CAMBRIDGE, Mass., May 21, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, today gave two oral presentations supporting its lead therapeutic candidate, Nexvax2®, at the Digestive Disease Week Annual Conference 2019 in San Diego. Nexvax2 is the most clinically-advanced potentially disease modifying therapeutic vaccine for people with celiac disease, currently in an ongoing global Phase 2 clinical trial.]]>https://www.globenewswire.com/news-release/2019/05/16/1826338/0/en/ImmusanT-to-Present-New-Findings-on-Celiac-Disease-and-Lead-Therapeutic-Candidate-During-the-Digestive-Disease-Week-Annual-Conference-2019.html?f=22&fvtc=4&fvtv=51401ImmusanT to Present New Findings on Celiac Disease and Lead Therapeutic Candidate During the Digestive Disease Week Annual Conference 20192019-05-16T14:35:50Z<![CDATA[CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, announced today the company will be presenting two abstracts supporting its lead therapeutic candidate, Nexvax2®, during the upcoming Digestive Disease Week Annual Conference 2019, being held in San Diego on May 18-21, 2019.]]>https://www.globenewswire.com/news-release/2019/03/21/1758756/0/en/ImmusanT-to-Present-and-Participate-in-Multiple-Upcoming-Industry-and-Scientific-Conferences.html?f=22&fvtc=4&fvtv=51401ImmusanT to Present and Participate in Multiple Upcoming Industry and Scientific Conferences2019-03-21T17:00:28Z<![CDATA[ImmusanT CEO Leslie Williams to speak on panel during the MassBio Annual “The State of Possible Conference”]]>https://www.globenewswire.com/news-release/2019/03/06/1748764/0/en/ImmusanT-to-Provide-Corporate-Overview-at-the-Cowen-Company-39th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=51401ImmusanT to Provide Corporate Overview at the Cowen & Company 39th Annual Health Care Conference2019-03-06T13:00:00Z<![CDATA[CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, today announced that Leslie Williams, Chief Executive Officer, will present a corporate overview at the Cowen & Company 39th Annual Healthcare Conference, taking place March 11-13 in Boston, Massachusetts.]]>https://www.globenewswire.com/news-release/2019/01/03/1680217/0/en/ImmusanT-Expands-Senior-Management-Team-with-Appointment-of-Thomas-A-Shea-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=51401ImmusanT Expands Senior Management Team with Appointment of Thomas A. Shea as Chief Financial Officer2019-01-03T14:47:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, announced today the appointment of Thomas A. Shea as the company’s chief financial officer (CFO). Mr. Shea brings more than 30 years of professional financial experience in the biopharmaceutical industry to ImmusanT where he will leverage his expertise to assist the company in its fundraising and partnering activities.]]>https://www.globenewswire.com/news-release/2019/01/02/1679660/0/en/ImmusanT-Secures-Fast-Track-Designation-for-Lead-Therapeutic-Vaccine-Candidate-Nexvax2-for-Patients-with-Celiac-Disease-CeD.html?f=22&fvtc=4&fvtv=51401ImmusanT Secures Fast-Track Designation for Lead Therapeutic Vaccine Candidate Nexvax2 for Patients with Celiac Disease (CeD)2019-01-02T15:17:00Z<![CDATA[Nexvax2 Has Been Designed to Potentially Restore Immune Tolerance to Gluten in Patients with CeD Nexvax2 Has Been Designed to Potentially Restore Immune Tolerance to Gluten in Patients with CeD]]>https://www.globenewswire.com/news-release/2018/12/07/1663929/0/en/ImmusanT-Chief-Scientific-Officer-Robert-Anderson-Ph-D-to-Participate-as-a-Featured-Speaker-During-the-Antigen-Specific-Immune-Tolerance-Europe-Conference-2018.html?f=22&fvtc=4&fvtv=51401ImmusanT Chief Scientific Officer Robert Anderson, Ph.D. to Participate as a Featured Speaker During the Antigen-Specific Immune Tolerance Europe Conference 20182018-12-07T17:53:26Z<![CDATA[CAMBRIDGE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, announced today that Robert (Bob) Anderson, Ph.D., will be among the featured speakers during the Antigen-Specific Immune Tolerance Europe Conference 2018 in London from Dec. 10-12, 2018.]]>https://www.globenewswire.com/news-release/2018/11/20/1654594/0/en/ImmusanT-CEO-Leslie-Williams-to-Present-at-Multiple-Life-Sciences-Events-to-Share-Company-s-Leadership-Position-in-the-Industry-and-Successful-Growth-Strategy.html?f=22&fvtc=4&fvtv=51401ImmusanT CEO Leslie Williams to Present at Multiple Life Sciences Events to Share Company’s Leadership Position in the Industry and Successful Growth Strategy2018-11-20T14:30:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases,]]>